National Center for Respiratory Medicine, Beijing, China.
State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Virulence. 2024 Dec;15(1):2348251. doi: 10.1080/21505594.2024.2348251. Epub 2024 May 2.
This study aimed at revealing the underlying mechanisms of the loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing hypervirulent (hvKp).
Here we longitudinally recovered 3 non-carbapenemase-producing K1-ST23 hvKp strains at a one-month interval (KP29105, KP29499 and KP30086) from an elderly male. Antimicrobial susceptibility testing, whole genome sequencing, transcriptomic sequencing, gene cloning, plasmid conjugation, quantitative real-time PCR (qRT-PCR), and SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) were conducted.
Among the 3 hvKp strains, KP29105 was resistant to the third- and fourth-generation cephalosporins, KP29499 acquired resistance to both ceftazidime-avibactam and carbapenems, while KP30086 restored its susceptibility to ceftazidime-avibactam, imipenem and meropenem but retained low-level resistance to ertapenem. KP29105 and KP29499 carried plasmid-encoded genes and , respectively, but KP30086 lost both. Cloning of gene and conjugation experiment of -carrying plasmid showed that the transformant and transconjugant were susceptible to ceftazidime-avibactam but had a more than 8-fold increase in MICs. Supplementation with an outer membrane permeabilizer could reduce the MIC of ceftazidime-avibactam by 32 folds, indicating that porins play a key role in ceftazidime-avibactam resistance. The OmpK35 of the 3 isolates was not expressed, and the OmpK36 of KP29499 and KP30086 had a novel amino acid substitution (L359R). SDS-PAGE and qRT-PCR showed that the expression of porin OmpK36 of KP29499 and KP30086 was significantly down-regulated compared with KP29105.
In summary, we reported the rare ceftazidime-avibactam resistance in a non-carbapenemase-producing hvKp strain. Resistance plasmid carrying and mutated OmpK36 had a synergetic effect on the resistance.
本研究旨在揭示非产碳青霉烯酶超毒力(hvKp)头孢他啶-阿维巴坦敏感性丧失和获得的潜在机制。
我们从一位老年男性患者中,以一个月为间隔,连续分离出 3 株非产碳青霉烯酶的 K1-ST23 hvKp 菌株(KP29105、KP29499 和 KP30086)(表 1)。进行药敏试验、全基因组测序、转录组测序、基因克隆、质粒接合、实时定量 PCR(qRT-PCR)和十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)。
在 3 株 hvKp 菌株中,KP29105 对第三代和第四代头孢菌素耐药,KP29499 对头孢他啶-阿维巴坦和碳青霉烯类均耐药,而 KP30086 恢复了对头孢他啶-阿维巴坦、亚胺培南和美罗培南的敏感性,但对厄他培南仍保持低水平耐药性。KP29105 和 KP29499 均携带质粒编码的基因 和 ,但 KP30086 两者均丢失。基因 的克隆和携带质粒的接合实验表明,转化子和转导子对头孢他啶-阿维巴坦敏感,但 MIC 增加了 8 倍以上。外膜通透性增强剂的添加可使头孢他啶-阿维巴坦的 MIC 降低 32 倍,表明孔蛋白在头孢他啶-阿维巴坦耐药中起关键作用。3 株分离株的 OmpK35 均不表达,而 KP29499 和 KP30086 的 OmpK36 有一个新的氨基酸取代(L359R)。SDS-PAGE 和 qRT-PCR 显示,与 KP29105 相比,KP29499 和 KP30086 的 OmpK36 孔蛋白表达明显下调。
综上所述,我们报道了非产碳青霉烯酶超毒力(hvKp)菌株中罕见的头孢他啶-阿维巴坦耐药性。携带 和 突变的 OmpK36 的耐药质粒具有协同作用。